Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients

Clinical Drug Investigation

Volumn 25, Issue 7, 2005, Pages 473-479

  Liau, Chiau Suong ^a   Lee, Chii Ming ^a   Sheu, Sheng Hsiung ^b   Ueng, Kwo Chang ^c   Chien, Kuo Liong ^a   Su, Ta Chen ^a   Lai, Wen Ter ^b   Lin, Ming Cheng ^c   Lin, Cheng Sheng ^c   Lin, Chung Sheng ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; OLMESARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; LABORATORY TEST; MALE; MULTICENTER STUDY; NECK PAIN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 22544483548     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525070-00006     Document Type: Article

References (24)

1. World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on man agement of hypertension. J Hypertens 2003; 21: 1983-92
2. National Heart, Lung, and Blood Institute, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7). JAMA 2003; 289: 2560-72
3. European Society of Hypertension-European Society of Cardiology. 2003 guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
4. MacMahon S, Peto R, Culter J, et al. Blood pressure, stroke, and coronary heart disease: prolonged differences in blood pressure. Lancet 1990; 335: 765-74
5. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615
6. Staessen JA, Wang JG, Thils L. Cardiovascular protection and blood pressure reduction. Lancet 2001; 358: 1305-15
7. Ruilope LM, Segura J. Renal protection by antihypertensive therapy. Curr Hypertens Rep 2002; 4: 324-8
8. Martins D, Norris K. Combating diabetic nephropathy with drug therapy. Curr Diab Rep 2001; 1: 148-56
9. Lee YT, Lin RS, Sung FC, et al. Chin-Shan Community Cardiovascular Cohort in Taiwan: baseline data and five-year follow-up morbidity and mortality. J Clin Epidemiol 2000; 53: 838-46
10. Liau CS, Tseng YZ, Lee TK. The prevalence of cardiovascular diseases in elderly Chinese people in Taiwan. Int J Cardiol 1998; 67: 177-81
11. Lu FH, Tang SJ, Wu JS, et al. Hypertension in elderly persons: its prevalence and associated cardiovascular risk factors in Tainan City, southern Taiwan. J Gerontol Med Sci 2000; 55A: M463-8
12. Burr VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
13. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4
14. Weber MA. Angiotensin II receptor blockers. In: Izzo Jr JL, Black HR, editors. Hypertension primer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003: 430-2
15. Chan P, Lin CN, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997; 10: 743-9
16. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 2001; 50: 1346-50
17. Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 2003; 25: 1041-55
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-45
19. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 -BSH IV. J Hum Hypertens 2004; 18: 139-85
20. Kaplan NM. Kaplan's clinical hypertension: treatment of hypertension: drug therapy. Philadelphia (PA): Lippincott Williams &Wilkins, 2002: 237-338
21. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91
22. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 Suppl. 1: S49-56
23. Stumpe KO, Ludwug M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 Suppl. 2: S24-8
24. Smith DH. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. J Hypertens 2002; 15: 108S-14S